Update on Osteoporosis and Fracture Prevention in Men and Women

This session will provide information regarding the identification of women and men at risk for fracture based on bone densitometry and their 10-year fracture risk using the FRAX calculation. Pharmacologic therapies will be reviewed including patient selection for first-line therapies and therapies for patients at extremely high risk and drug risks and benefits. Current controversies will be discussed including long-term use of bisphosphonates, adverse events including osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures, and drug holidays. New concerns about the discontinuation of rank ligand inhibitors and the rapid increase in vertebral fractures will be discussed. Treatment of patients at high risk due to therapy such as aromatase inhibitors and androgen deprivation therapy will be presented. Case studies will be used to provide real clinical scenarios.

Credits: 1.00 contact hours; 0.66 are pharmacology
Expiration Date: December 31, 2024

$30

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-Discuss the diagnosis of osteoporosis and low bone mass using bone density testing and FRAX.

-Discuss the pharmacologic treatment of low bone mass and osteoporosis.

-Discuss the pharmacologic treatment of low bone mass and osteoporosis.

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 0.66 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Nancy Berman, MSN, ANP-BC, NCMP, FAANP have disclosed:

1. Name of Commercial Interest/Company: Myovant
Relationship with Commercial Interest: Advisory Board
Clinical Area: Heavy Menstrual Bleeding with fibroids
Name of Drug, Test, Device or Other Product Made by Commercial Interest: Myfembree

2. Name of Commercial Interest/Company: Dysis
Relationship with Commercial Interest: Consultant
Clinical Area: Spectral Imaging Colposcopy
Name of Drug, Test, Device or Other Product Made by Commercial Interest: Dysis Spectroscopic Colposcope

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.